Sigma Planning Corp boosted its position in shares of IN8bio, Inc. (NASDAQ:INAB – Free Report) by 42.0% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 851,280 shares of the company’s stock after purchasing an additional 251,600 shares during the quarter. Sigma Planning Corp owned approximately 1.82% of IN8bio worth $230,000 at the end of the most recent reporting period.
IN8bio Stock Down 0.2 %
INAB opened at $0.34 on Monday. The firm has a market cap of $15.69 million, a P/E ratio of -0.45 and a beta of -0.07. The business’s fifty day simple moving average is $0.30 and its 200 day simple moving average is $0.67. IN8bio, Inc. has a 52 week low of $0.22 and a 52 week high of $2.48. The company has a quick ratio of 2.66, a current ratio of 1.84 and a debt-to-equity ratio of 0.05.
IN8bio (NASDAQ:INAB – Get Free Report) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.01). As a group, equities research analysts anticipate that IN8bio, Inc. will post -0.56 EPS for the current fiscal year.
Analyst Ratings Changes
Read Our Latest Analysis on INAB
About IN8bio
IN8bio, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidates include INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation; and INB-400, which is in Phase 2 clinical trial to treat newly diagnosed GBM.
Featured Articles
- Five stocks we like better than IN8bio
- How to Invest in the Best Canadian Stocks
- Warren Buffett, Cathie Wood Own Nu Holdings, Should You?
- How to Invest in Blue Chip Stocks
- MercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?
- What is the Shanghai Stock Exchange Composite Index?
- ORIC: Working with Two Pharma Giants, Analysts See +100% Upside
Want to see what other hedge funds are holding INAB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IN8bio, Inc. (NASDAQ:INAB – Free Report).
Receive News & Ratings for IN8bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IN8bio and related companies with MarketBeat.com's FREE daily email newsletter.
